Sopoongsan Attenuates Chronic Pruritus via STAT1 Inhibition: Evidence from a Randomized Pilot Trial and Translational Models
Posted inAllergy & Immunology Dermatology news

Sopoongsan Attenuates Chronic Pruritus via STAT1 Inhibition: Evidence from a Randomized Pilot Trial and Translational Models

A pilot randomized controlled trial and translational study demonstrate that Sopoongsan (SPS) effectively reduces chronic upper body pruritus in atopic and seborrheic dermatitis by inhibiting STAT1-mediated inflammatory pathways, offering a promising evidence-based herbal intervention for recalcitrant skin inflammation.
Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment
Posted inAllergy & Immunology Dermatology news

Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment

A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable safety profile with minimal systemic absorption, offering a promising new topical JAK inhibitor option.
Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa
Posted inAllergy & Immunology Dermatology news

Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa

The SHINE trial, despite missing its primary endpoint due to a high placebo response, suggests that high-dose vilobelimab significantly reduces draining tunnels in moderate-to-severe hidradenitis suppurativa, offering a potential new therapeutic avenue for structural skin damage.
Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial
Posted inAllergy & Immunology Dermatology news

Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial

A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both treatments showing favorable safety profiles.
Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care
Posted inAllergy & Immunology Clinical Updates news Respiratory

Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care

This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocating for a holistic approach to complex patient management.
Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial
Posted inAllergy & Immunology news Respiratory

Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial

The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammatory biomarkers.
Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids
Posted inAllergy & Immunology news Respiratory

Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids

The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new evidence base for anti-inflammatory reliever strategies in moderate asthma.